Does Cigna Cover Trazodone? Formulary Tier, Prior Authorization, and Appeal Steps

Trazodone hydrochloride (brand name Desyrel; the extended-release brand Oleptro has been discontinued in the US) is a generic serotonin antagonist and reuptake inhibitor (SARI) approved by the FDA for major depressive disorder. Most Cigna commercial, employer-sponsored, and Medicare Advantage Part D plans place generic trazodone tablets on their lowest-cost generic formulary tier, and most do not require prior authorization for the standard immediate-release tablet at usual antidepressant or off-label sleep doses. This is a general pattern across large-formulary insurers for an inexpensive, decades-old generic, not a Cigna-specific guarantee. Coverage details vary by employer group, plan year, and state, so the tier, copay, and any utilization-management rules on your specific plan should be confirmed directly with Cigna rather than assumed from this article.

The more useful question for most readers is not "does Cigna cover trazodone" but "does my plan treat off-label insomnia dosing, high-dose regimens, or compounded formulations differently than standard antidepressant dosing." That is where coverage friction, if any, tends to show up.

What is actually established versus what needs plan-level verification

Established, from FDA labeling and general pharmacy benefit design:

• Trazodone is FDA-approved for major depressive disorder. Prescribing it for insomnia at lower doses (commonly cited in clinical practice as roughly 25 to 100 mg) is an off-label use, meaning the FDA has not evaluated or approved it specifically for that indication.
• Generic drugs that have been off-patent for decades are almost always placed on an insurer's lowest cost-sharing tier, and trazodone has been available generically since shortly after Desyrel's original approval in the early 1980s.
• A documented, medically urgent side effect of trazodone is priapism (a prolonged, painful erection), which requires emergency care. This is described in the drug's official labeling and in NIH consumer drug information; exact incidence figures vary between sources and should not be quoted as a precise number without checking the current label.

Plausible but plan-dependent, requiring verification with Cigna directly:

• Exact copay amounts, whether your plan is Tier 1 or Tier 2, and whether prior authorization applies. These are set by each employer group's specific benefit design and can change at renewal.
• Whether high-dose trazodone (above the labeled maximum) or concurrent sedating medications trigger a utilization-management review. This is plausible given how pharmacy benefit managers generally handle sedative-hypnotic overlap, but the specific threshold on a given Cigna plan is not something this article can confirm without pulling that plan's current formulary document.
• Whether compounded trazodone preparations require precertification. Compounded drugs generally fall outside standard formulary tiers across most insurers, but Cigna's specific process should be confirmed with the pharmacy benefit team.

Not established here:

• Any specific dollar figure for cash price, copay, or brand-name sleep drug pricing. Prices change and vary by pharmacy, region, and plan year; quoting a fixed number without a date and source risks being wrong by the time a reader acts on it. Use a current pricing tool or your Cigna member portal for an accurate number on the date you need it.

How Cigna generally classifies trazodone on its formulary

Large commercial insurers, including Cigna, typically place long-generic, low-cost drugs like trazodone tablets on a preferred generic tier (often labeled Tier 1, sometimes Tier 2 depending on the employer's plan design). This tends to carry the lowest fixed copay or coinsurance available under that plan. Extended-release or compounded versions of trazodone are less predictable: since the brand ER product (Oleptro) is discontinued, any extended-release trazodone dispensed today is typically compounded, and compounded medications commonly sit outside standard tier structures and may require additional documentation.

To get an answer specific to your plan, the reliable path is direct verification: call the number on your Cigna ID card and ask pharmacy benefits whether trazodone is on your formulary, what tier it is, and whether prior authorization applies, or check the formulary lookup tool at myCigna.com. Formularies are typically updated annually, and mid-year changes can occur if an employer adjusts its benefit design.

When prior authorization or step therapy might apply

Standard-dose generic trazodone tablets prescribed for FDA-approved depression treatment do not typically require prior authorization on most large commercial formularies, because the drug is inexpensive and has a long safety track record. Prior authorization becomes more likely in a few scenarios that are common across insurers generally, not unique to Cigna:

• The prescription is for a compounded formulation rather than a standard manufactured tablet
• The prescribed dose exceeds the labeled maximum daily dose (confirm the current maximum on the FDA label, since dosing guidance can be revised)
• The prescription overlaps with other sedating medications, which some pharmacy benefit managers flag for a safety review

Step therapy, where a patient must try and fail a cheaper drug before a costlier one is approved, is not typically applied to trazodone itself because it is already one of the least expensive options in its class. If anything, trazodone is more often the drug that step-therapy rules require patients to try before approving a newer branded insomnia medication such as suvorexant or lemborexant. Whether that applies to a specific plan needs to be confirmed against that plan's specific step-therapy list.

Off-label insomnia prescribing: what's clinically established and what's a coverage judgment call

Trazodone is widely used off-label for insomnia in the United States, and multiple published analyses of prescribing patterns have found it among the most frequently prescribed medications for sleep complaints, despite lacking an FDA insomnia indication. Guideline bodies in sleep medicine have historically noted that the evidence supporting trazodone as a hypnotic is weaker and less consistent than the evidence behind medications that are actually FDA-approved for insomnia. That gap between prescribing frequency and strength of evidence is worth knowing before assuming off-label use is risk-free or automatically well supported.

From a coverage standpoint, insurers generally do not block off-label prescribing of a low-cost generic the way they might scrutinize an expensive off-label use, because the financial exposure is minimal. That is a reasonable inference about typical pharmacy benefit behavior, not a confirmed Cigna policy statement, and it does not mean every plan handles it identically.

What you're likely to pay, and why a specific number here would mislead you

Generic trazodone is one of the least expensive oral antidepressants available, and copays for lowest-tier generics are typically small or, on some plans with $0 generic tiers, nothing at all. Beyond that general statement, this article intentionally avoids quoting specific cash prices or copay ranges, because retail prices vary by pharmacy and region, plan designs change at renewal, and an outdated or unverified number stated with false precision is more likely to mislead a reader than a plan lookup would be. Check your Cigna Explanation of Benefits, the myCigna cost estimator tool, or ask your pharmacist for the current price and your specific copay before filling.

Because trazodone is dispensed almost exclusively as a generic, manufacturer copay assistance cards, which apply only to brand-name drugs, generally do not apply here. If your prescriber has written for a brand-name or compounded version and the cost is high, it is reasonable to ask whether the standard generic immediate-release tablet is clinically appropriate instead.

How to appeal a Cigna denial

Denials for standard generic trazodone are uncommon given its low cost and established use, but they can occur, particularly with compounded formulations, doses above the labeled maximum, or specific employer plan exclusions. The general appeals framework that applies to ACA-regulated and most employer-sponsored plans, including Cigna's, works in stages:

1. Read the denial letter carefully. Cigna is required to issue a written Adverse Benefit Determination explaining the specific reason for denial, whether that is a plan exclusion, a missing prior authorization, or a dose outside formulary limits.
2. File an internal appeal. Have your prescriber submit a letter of medical necessity that documents the diagnosis, prior treatments tried, and any contraindications to alternative medications. Cigna's internal appeal process generally allows more than one level of review.
3. Request an external review if internal appeals fail. Federal law entitles patients to an Independent Review Organization (IRO) review after exhausting internal appeals, and the IRO's decision is binding on the plan. There is generally a filing deadline measured in months from the final internal denial, so act promptly once you receive that letter.

General guidance on appeal rights and plan obligations under federal marketplace and group health plan rules is available from the Centers for Medicare & Medicaid Services. The exact appeal deadlines and forms for your situation should come from the denial letter itself and your state insurance department, since these can vary.

Cigna Medicare Advantage and Part D

Cigna Medicare Advantage plans with drug coverage follow CMS Part D formulary rules, and generic drugs like trazodone are typically placed on the lowest Part D tier. Cost-sharing during the initial coverage phase, the coverage gap, and for members enrolled in the Extra Help low-income subsidy program differs by phase and by plan, and these figures are set and updated by CMS and by each plan's approved formulary. Rather than restate specific dollar amounts here, which change with plan year, verify current cost-sharing through your Cigna Medicare plan's Evidence of Coverage document or the CMS Medicare Plan Finder.

Safety context relevant to a coverage conversation

Trazodone's side-effect profile is part of why insurers generally do not restrict it heavily, but it is also relevant to whether it is the right choice for a given patient, which is a clinical decision separate from a coverage decision. Commonly reported effects include next-day sedation, which is more likely at higher hypnotic doses, and orthostatic hypotension, which is more common in older adults and raises fall risk. Priapism is a rare but medically urgent adverse effect that requires immediate care; it is documented in the FDA label and in NIH consumer drug information, and any male patient experiencing a prolonged, painful erection should seek emergency treatment rather than waiting to discuss it at a routine visit. This article does not provide individualized dosing guidance; dose selection and any change in dose should be made with a prescriber based on the patient's full history.

Trazodone also carries interaction risks with other serotonergic medications (serotonin syndrome risk) and with other CNS depressants (additive sedation risk). These are established pharmacologic concerns independent of insurance coverage and are a reason a clinician, not a benefits representative, should confirm that trazodone is appropriate for a specific patient's medication list.

Decision guide: which trazodone coverage situation are you in?

Use this to identify which path applies before you call Cigna or ask your prescriber to intervene.

When to seek care instead of pursuing coverage questions

If you or someone taking trazodone develops a prolonged and painful erection, signs of serotonin syndrome (agitation, rapid heart rate, high fever, muscle rigidity), fainting, or a significant fall related to dizziness, seek emergency care immediately. These are clinical emergencies that take priority over any insurance or formulary question.